Protecting Against Hearing Loss: Acousia Pursues A New Approach
Executive Summary
German biotech Acousia Therapeutics closes a series B round with corporate and institutional VC firms, and aims to advance its drugs into clinical trials for hearing loss associated with cancer chemotherapy.
You may also be interested in...
Boehringer Doubles Down On Deafness With Rinri Backing
After making a move into hearing loss with an investment into Acousia Therapeutics, BI is backing a UK biotech which hopes to reverse neuropathic sensorineural hearing loss.
Pharma Wakes Up To Transformative Progress In Hearing Loss Research
The cacophony of noise in the modern world is one factor driving the loss of hearing throughout humankind, a condition that until now has not been thought amenable to pharmacological intervention. But with small-molecule approaches to regenerating cells in the inner ear bearing fruit, biotech and pharmaceutical companies are taking renewed interest in the sector.
Pharma Wakes Up To Transformative Progress In Hearing Loss Research
The cacophony of noise in the modern world is one factor driving the loss of hearing throughout humankind, a condition that until now has not been thought amenable to pharmacological intervention. But with small-molecule approaches to regenerating cells in the inner ear bearing fruit, biotech and pharmaceutical companies are taking renewed interest in the sector.